{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T11:56:03Z","timestamp":1768996563058,"version":"3.49.0"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    A 62-year-old man with prostate cancer underwent both\n                    <jats:sup>18<\/jats:sup>\n                    F-PSMA-1007 and\n                    <jats:sup>18<\/jats:sup>\n                    F-fluorocholine PET\/CT studies for biochemical recurrence.\n                    <jats:sup>18<\/jats:sup>\n                    F-PSMA-1007 PET\/CT outperformed\n                    <jats:sup>18<\/jats:sup>\n                    F-fluorocholine PET\/CT in detecting lymph node metastases in the pelvis and retroperitoneum, whereas the former showed a focus of increased uptake in the spleen not seen on\n                    <jats:sup>18<\/jats:sup>\n                    F-fluorocholine. The\n                    <jats:sup>18<\/jats:sup>\n                    F-PSMA-1007 \u2013avid lesion corresponded to a splenic hemangioma, which was initially detected in an MRI scan 10 years ago, unchanged in size. This case shows different features of\n                    <jats:sup>18<\/jats:sup>\n                    F-PSMA-1007 and\n                    <jats:sup>18<\/jats:sup>\n                    F-fluorocholine uptake, in an incidentally detected splenic hemangioma, alerting PET\/CT reports for possible pitfall.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000003310","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T15:08:20Z","timestamp":1602860900000},"page":"960-961","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["False-Positive 18F-PSMA-1007 and True-Negative 18F-Fluorocholine PET\/CT Splenic Hemangioma"],"prefix":"10.1097","volume":"45","author":[{"given":"Emmanouil","family":"Panagiotidis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Paschali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xanthi","family":"Xourgia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vassiliki","family":"Chatzipavlidou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"key":"bib1-20260120","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1148\/rg.2018170108","article-title":"Prostate-specific membrane antigen PET: clinical utility in prostate cancer, Normal patterns, pearls, and pitfalls","volume":"38","year":"2018","journal-title":"Radiographics"},{"key":"bib2-20260120","first-page":"2674","article-title":"Prostate-specific membrane antigen is produced in tumor-associated neovasculature","volume":"5","year":"1999","journal-title":"Clin Cancer Res"},{"key":"bib3-20260120","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.1128\/MCB.00084-06","article-title":"Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction","volume":"26","year":"2006","journal-title":"Mol Cell Biol"},{"key":"bib4-20260120","doi-asserted-by":"crossref","first-page":"e629","DOI":"10.1097\/RLU.0000000000002794","article-title":"Head-to-head comparison of 18F\u2013prostate-specific membrane antigen-1007 and 18F-fluorocholine PET\/CT in biochemically relapsed prostate cancer","volume":"44","year":"2019","journal-title":"Clin Nucl Med"},{"key":"bib5-20260120","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/RLU.0000000000002428","article-title":"Splenic hemangioma as a potential pitfall on PSMA-targeted 18F-DCFPyL PET\/CT","volume":"44","year":"2019","journal-title":"Clin Nucl Med"},{"key":"bib6-20260120","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/RLU.0000000000002662","article-title":"Incidental detection of splenic hemangioma on 68Ga-PSMA PET\/CT","volume":"44","year":"2019","journal-title":"Clin Nucl Med"},{"key":"bib7-20260120","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1097\/RLU.0000000000001384","article-title":"Prostate-specific membrane antigen PET\/CT findings for hepatic hemangioma","volume":"41","year":"2016","journal-title":"Clin Nucl Med"},{"key":"bib8-20260120","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1097\/RLU.0000000000001542","article-title":"Subcutaneous lobular capillary hemangioma on 68Ga-PSMA PET\/CT","volume":"42","year":"2017","journal-title":"Clin Nucl Med"},{"key":"bib9-20260120","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/RLU.0000000000001631","article-title":"Vertebral hemangioma mimicking bone metastasis in 68Ga-PSMA ligand PET\/CT","volume":"42","year":"2017","journal-title":"Clin Nucl Med"},{"key":"bib10-20260120","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/RLU.0000000000001731","article-title":"Extraosseous extension of aggressive vertebral hemangioma as a potential pitfall on 68Ga-PSMA PET\/CT","volume":"42","year":"2017","journal-title":"Clin Nucl Med"},{"key":"bib11-20260120","first-page":"1","article-title":"Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings","volume":"20","year":"2020","journal-title":"Cancer Imaging"},{"key":"bib12-20260120","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4103\/ijnm.IJNM_81_18","article-title":"Nonspecific uptake of 68Ga\u2013prostate-specific membrane antigen in diseases other than prostate malignancy on positron emission tomography\/computed tomography imaging: a pictorial assay and review of literature","volume":"33","year":"2018","journal-title":"Indian J Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003310","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T22:00:27Z","timestamp":1768946427000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":12,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003310","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,15]]}}}